Behavioral Outcomes and Neurodevelopmental Disorders Among Children of Women With Epilepsy
Morris J Cohen,Kimford J Meador,David W Loring,Abigail G Matthews,Carrie Brown,Chelsea P Robalino,Angela K Birnbaum,Paula E Voinescu,Laura A Kalayjian,Elizabeth E Gerard,Evan R Gedzelman,Julie Hanna,Jennifer Cavitt,Maria C Sam,Jacqueline A French,Sean T Hwang,Alison M Pack,Page B Pennell,Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Investigator Group,Maurice Druzin,Richard Finnell,Gregory Holmes,Frederick T McElrath,Lorene Nelson,Zachary Stowe,Linda Van Marter,Peter Wells,Mark Yerby,Eugene Moore,Ryan May,Dominic Ippolito,Julia Skinner,Lisa Davis,Nilay Shah,Brenda Leung,Mark Friedman,Hayley Loblein,Traci Sheer,Yue Wang,Nancy Browning,Michelle Arias,Rebecca Ayre,Temperance Blalock,Linda Hendrickson,Merin Mathew,Anjali Nair,Yinka Ogunsola,Chinh Ott,Phyllis Zaia Renehan,Sarah Romano,Dominic Schutte,Noble Shore,Vydhi Vasudevan,Steffanie Wilson,Jamie Winestone,Thad Zajdowicz,Suzanne Strickland,Erin Latif,Yong Park,Delmaris Acosta-Cotte,Patty Ray,Kirsten Cleary,Joyce Echo,Annette Zygmunt,Camilla Casadei,Ifemoa Irobunda,Anna Chessky,Mary Dolan,Kim Ono,Donald Bearden,Christine Ghilian,Diane Teagarden,Melanee Newman,Yvan Bamps,Emilee Wehunt,Paul McCabe,Michael Paglia,Cora Taylor,Rosemarie Delucca,Kristina Blessing,Joshua Dopko,Katrina Boyer,Ellen Hanson,Amy Young,Paige Hickey,Jolie Strauss,Hayley Madeiros,Brian Rozumny,Li Chen,Stephanie Allien,Yvonne Sheldon,Taylor Weinau,Elizabeth Shashkova,Melanie Choe,Gregory L Barkley,Marianna Spanaki-Varelas,Andrea Thomas,Jules Constantinou,Nazin Mahmood,Vibhangini Wasade,Shailaja Gaddam,Andrew Zillgitt,Taimur Anwar,Carla Sandles,Theresa Holmes,Emily Johnson,Gregory Krauss,Shari Lawson,Alison Pritchard,Matthew Ryan,Pam Coe,Katie Reger,Jenny Pohlman,Alisha Olson,Anna Steele,Hadley Lange,Patricia Chang,Sarah Ellis,William Schweizer,Chris Morrison,William MacAllister,Tobi Clements,Edward Riley,Aaron Smith,Maria Pleskovich,Hima Bindu Tam Tam,Yael Cukier Cukier,Erica Meltzer Meltzer,Jacqueline Helcer Helcer,Connie Lau Lau,Scott Baron,Olivia Colon,William Grobman,Joseph Coda,Emily Miller,Irena Bellinski,Elizabeth Bachman,Casey Krueger,Jordan Seliger,Jennifer DeWolfe,John Owen,Matthew Thompson,Cheryl Hall,Valencia Williams,Anna Moyana,David Labiner,James Maciulla,Jennifer Moon,Kayla Darris,Alicia Bahe,Scott Richards,Michael Privitera,Kellie Flood-Schaffer,George Jewell,Lucy Mendoza,Becky Mcelroy,Enrique Serrano,Yasin Salih,Christin Bermudez,Michelle Miranda,Naymee Velez-Ruiz,Pedro Figueredo,Danielle Carns,Scott Harcourt,Kristin Ramirez,Leticia Tedesco Silva,Anto Bagic,Alexandra Urban,Satya Gedela,Christina Patterson,Arundhathi Jeyabalan,Krestin Radonovich,Melissa Sutcliffe,Susan Beers,Carrie Wiles,Sabrina Duran,Dane Prince,Sandra Alhaj,Alice Stek,Sonia Perez,Rachel Sierra,Cynthia Munoz,John W Miller,Jennie Mao,Vaishali Phatak,Michelle Kim,Andrea Cheng-Hakimian,Gina DeNoble,Jeffrey Tsai,Erin Anthony-Fick,Jennifer Steele,Lamar Parker,Melissa Morris,Jessica Dimos,Deanna Oates,Danielle Culbreth
DOI: https://doi.org/10.1001/jamaneurol.2023.4315
2024-01-01
Abstract:Importance: The association of fetal exposure to antiseizure medications (ASMs) with outcomes in childhood are not well delineated. Objective: To examine the association of fetal ASM exposure with subsequent adaptive, behavioral or emotional, and neurodevelopmental disorder outcomes at 2, 3, and 4.5 years of age. Design, setting, and participants: The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study is a prospective, observational cohort study conducted at 20 epilepsy centers in the US. A total of 456 pregnant women with epilepsy or without epilepsy were enrolled from December 19, 2012, to January 13, 2016. Children of enrolled women were followed up with formal assessments at 2, 3, 4.5, and 6 years of age. Statistical analysis took place from August 2022 to May 2023. Exposures: Exposures included mother's epilepsy status as well as mother's ASM blood concentration in the third trimester (for children of women with epilepsy). Women with epilepsy were enrolled regardless of ASM regimen. Main outcomes and measures: The primary outcome was the Adaptive Behavior Assessment System, Third Edition (ABAS-3) General Adaptive Composite (GAC) score among children at 4.5 years of age. Children of women with epilepsy and children of women without epilepsy were compared, and the associations of ASM exposures with outcomes among exposed children were assessed. Secondary outcomes involved similar analyses of other related measures. Results: Primary analysis included 302 children of women with epilepsy (143 boys [47.4%]) and 84 children of women without epilepsy (45 boys [53.6%]). Overall adaptive functioning (ABAS-3 GAC score at 4.5 years) did not significantly differ between children of women with epilepsy and children of women without epilepsy (parameter estimate [PE], 0.4 [95% CI, -2.5 to 3.4]; P = .77). However, in adjusted analyses, a significant decrease in functioning was seen with increasing third-trimester maximum ASM blood concentrations (PE, -7.8 [95% CI, -12.6 to -3.1]; P = .001). This decrease in functioning was evident for levetiracetam (PE, -18.9 [95% CI, -26.8 to -10.9]; P < .001) and lamotrigine (PE, -12.0 [95% CI, -23.7 to -0.3]; P = .04), the ASMs with sample sizes large enough for analysis. Results were similar with third-trimester maximum daily dose. Conclusions and relevance: This study suggests that adaptive functioning of children of women with epilepsy taking commonly used ASMs did not significantly differ from that of children of women without epilepsy, but there was an exposure-dependent association of ASMs with functioning. Thus, psychiatric or psychological screening and referral of women with epilepsy and their offspring are recommended when appropriate. Additional research is needed to confirm these findings.